COLLEGE PARK, Md., and EAST RUTHERFORD, N.J., Oct. 4
/PRNewswire-FirstCall/ -- Innovative Biosensors, Inc. (IBI), a company
developing rapid, ultra-sensitive tests to detect harmful pathogens, and
Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation
(NYSE: CBM), today announced that they have signed an agreement for Cambrex to
supply cGMP manufacturing services.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
Innovative Biosensors, Inc. develops, manufactures, and markets pathogen
tests for infectious diseases within the food safety and human clinical
markets. Under the agreement, Cambrex Bio Science will provide cGMP (current
Good Manufacturing Processes) production services for the manufacture of IBI's
human clinical testing reagents. Production will take place in Cambrex's
Walkersville, Maryland, facility.
"We are proud to be IBI's partner and believe that their technology has
great potential. This is the first agreement where we will supply our
cell-based cGMP manufacturing services, usually provided to therapeutic
companies, to a client with innovative pathogen detection products. We
believe our experience and infrastructure can help Innovative Biosensors jump
start the product commercialization process," commented Shawn Cavanagh, Senior
Vice President and General Manager, Cambrex Bioproducts.
"Cambrex's state-of-the-art facilities and scale-up expertise are among
the many advantages of this manufacturing relationship," said Joe Hernandez,
IBI's President and CEO. "Cambrex's commitment to quality through cGMP and
Lean Six Sigma will quicken the commercialization of our human clinical
diagnostic products."
About Cambrex Corporation
Cambrex Corporation (NYSE: CBM) is a global, diversified life science
company dedicated to providing products and services to accelerate the
discovery and commercialization of human therapeutics. The company employs
approximately 1,900 people worldwide. For more information, visit
http://www.cambrex.com.
Cambrex Forward Looking Statements
This news release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under
The Securities Exchange Act of 1934, including, without limitation, statements
regarding expected performance, especially expectations with respect to sales,
research and development expenditures, earnings per share, capital
expenditures, acquisitions, divestitures, collaborations, or other expansion
opportunities. These statements may be identified by the fact that words such
as "expects", "anticipates", "intends", "estimates", "believes" or similar
expressions are used in connection with any discussion of future financial and
operating performance. The forward-looking statements contained herein are
based on current plans and expectations and involve risks and uncertainties
that could cause actual outcomes and results to differ materially from current
expectations including but not limited to, global economic trends,
pharmaceutical outsourcing trends, competitive pricing or product
developments, government legislation and/or regulations (particularly
environmental issues), tax rate, technology, manufacturing and legal issues,
changes in foreign exchange rates, performance of minority investments, un-
collectable receivables, loss on disposition of assets, cancellation or delays
in renewal of contracts, and lack of suitable raw materials or packaging
materials. For further details and a discussion of these and other risks and
uncertainties, investors are cautioned to review the Cambrex Annual Report on
Form 10-K, including the Forward-Looking Statement section therein, and other
filings with the Securities and Exchange Commission. The Company undertakes
no obligation to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise.
About Innovative Biosensors, Inc.
Innovative Biosensors, Inc. is a privately held company developing novel
technologies for the rapid detection of pathogens. The company's technology
is expected to have broad applications in food testing, animal health, and
human health care, including drug discovery and development and disease
diagnosis. Additional information is available at
http://www.innovativebiosensors.com.
Innovative Biosensors, Inc. Forward Looking Statements
This release may contain forward-looking statements that are subject to
certain risks and uncertainties, including Innovative Biosensors' mission to
develop and commercialize instrument systems, Innovative Biosensors' ability
to develop new technologies to conduct rapid diagnosis. Such statements are
based on management's current expectations and are subject to a number of
factors and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements. Innovative Biosensors
cautions investors that there can be no assurance that actual results or
business conditions will not differ materially from those projected or
suggested in such forward-looking statements as a result of various factors,
including, but not limited to, the following: Innovative Biosensors'
expectations that they will incur operating losses in the near future, the
early stage of development of Innovative Biosensors' products and
technologies, uncertainties related to preclinical and clinical testing and
trials, uncertainties surrounding the availability of additional funding,
Innovative Biosensors' reliance on research collaborations, the actions of
competitors and the development of competing technologies, potential patent
infringement claims against Innovative Biosensors' products, processes and
technologies, Innovative Biosensors' ability to protect their patents and
proprietary rights and uncertainties relating to commercialization rights.
SOURCE Cambrex Corporation
 back to top
Related links:
http://www.cambrex.com
http://www.innovativebiosensors.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO
Company News On-Call:
http://www.prnewswire.com/comp/134219.html
CONTACT:
Anne-Marie Hess of Cambrex, +1-201-804-3062,
annemarie.hess@cambrex.com; or Hollie Kephart, Media Relations of
Innovative Biosensors, Inc., +1-301-405-8444,
info@innovativebiosensors.com
|
